中国综合临床
中國綜閤臨床
중국종합림상
Clinical Medicine of China
2015年
11期
969-972
,共4页
霍江涛%张小乔%严洁%潘庆敏%陈敏
霍江濤%張小喬%嚴潔%潘慶敏%陳敏
곽강도%장소교%엄길%반경민%진민
阿尔茨海默病%美金刚%多奈哌齐%疗效
阿爾茨海默病%美金剛%多奈哌齊%療效
아이자해묵병%미금강%다내고제%료효
Alzheimer's disease%Memantine%Donepezil%Curative effect
目的 探讨美金刚联合多奈哌齐治疗中、重度阿尔茨海默病的临床效果和安全性,为临床治疗提供依据.方法 收集112例中、重度阿尔茨海默病患者,将患者随机分为观察组(美金刚联合多奈哌齐治疗组)和对照组(美金刚治疗组),疗程分别为24周.分别于治疗前、后给予简易智能精神状态量表(MMSE)、阿尔茨海默病评估量表-认知部分(ADAS-cog)、阿尔茨海默病协作学习-日常生活能力问卷(ADCS-ADL)、神经精神科问卷(NPI)评分,并评价两种治疗方法的安全性和有效性.结果 观察组患者治疗后MMSE、ADAS-cog、ADL、NPI评分分别为(12.1±2.1)、(32.9±8.3)、(33.4±5.0)、(6.1±3.1)分,较治疗前(9.9±2.8)、(46.2±7.6)、(42.1±6.0)、(10.5±2.9)分均有明显改善,治疗前、后比较差异均有统计学意义(t值分别为2.138、-2.411、2.398、2.107,P均＜0.05);对照组患者治疗后MMSE、ADAS-cog、ADL、NPI评分分别为(12.3±2.6)、(33.1±7.2)、(35.1±6.6)、(6.7±2.9)分,较治疗前(11.0±2.5)、(44.9±6.9)、(42.2±6.6)、(10.9±3.5)分均有明显改善,治疗前、后比较差异均有统计学意义(t值分别为2.101、-2.033、2.105、2.400,P均＜0.05);两组患者治疗后MMSE、NPI评分比较差异有统计学意义(t值分别为2.553、2.176,P均＜0.05).观察组和对照组患者不良反应发生率分别为32.14％(18/56)、26.79％ (15/56),两组比较差异无统计学意义(P＞0.05).结论 美金刚联用多奈哌齐治疗中、重度阿尔茨海默病患者的效果明显优于单用美金刚的效果,且长期应用并不增加不良反应出现的风险,联合应用安全、有效.
目的 探討美金剛聯閤多奈哌齊治療中、重度阿爾茨海默病的臨床效果和安全性,為臨床治療提供依據.方法 收集112例中、重度阿爾茨海默病患者,將患者隨機分為觀察組(美金剛聯閤多奈哌齊治療組)和對照組(美金剛治療組),療程分彆為24週.分彆于治療前、後給予簡易智能精神狀態量錶(MMSE)、阿爾茨海默病評估量錶-認知部分(ADAS-cog)、阿爾茨海默病協作學習-日常生活能力問捲(ADCS-ADL)、神經精神科問捲(NPI)評分,併評價兩種治療方法的安全性和有效性.結果 觀察組患者治療後MMSE、ADAS-cog、ADL、NPI評分分彆為(12.1±2.1)、(32.9±8.3)、(33.4±5.0)、(6.1±3.1)分,較治療前(9.9±2.8)、(46.2±7.6)、(42.1±6.0)、(10.5±2.9)分均有明顯改善,治療前、後比較差異均有統計學意義(t值分彆為2.138、-2.411、2.398、2.107,P均＜0.05);對照組患者治療後MMSE、ADAS-cog、ADL、NPI評分分彆為(12.3±2.6)、(33.1±7.2)、(35.1±6.6)、(6.7±2.9)分,較治療前(11.0±2.5)、(44.9±6.9)、(42.2±6.6)、(10.9±3.5)分均有明顯改善,治療前、後比較差異均有統計學意義(t值分彆為2.101、-2.033、2.105、2.400,P均＜0.05);兩組患者治療後MMSE、NPI評分比較差異有統計學意義(t值分彆為2.553、2.176,P均＜0.05).觀察組和對照組患者不良反應髮生率分彆為32.14％(18/56)、26.79％ (15/56),兩組比較差異無統計學意義(P＞0.05).結論 美金剛聯用多奈哌齊治療中、重度阿爾茨海默病患者的效果明顯優于單用美金剛的效果,且長期應用併不增加不良反應齣現的風險,聯閤應用安全、有效.
목적 탐토미금강연합다내고제치료중、중도아이자해묵병적림상효과화안전성,위림상치료제공의거.방법 수집112례중、중도아이자해묵병환자,장환자수궤분위관찰조(미금강연합다내고제치료조)화대조조(미금강치료조),료정분별위24주.분별우치료전、후급여간역지능정신상태량표(MMSE)、아이자해묵병평고량표-인지부분(ADAS-cog)、아이자해묵병협작학습-일상생활능력문권(ADCS-ADL)、신경정신과문권(NPI)평분,병평개량충치료방법적안전성화유효성.결과 관찰조환자치료후MMSE、ADAS-cog、ADL、NPI평분분별위(12.1±2.1)、(32.9±8.3)、(33.4±5.0)、(6.1±3.1)분,교치료전(9.9±2.8)、(46.2±7.6)、(42.1±6.0)、(10.5±2.9)분균유명현개선,치료전、후비교차이균유통계학의의(t치분별위2.138、-2.411、2.398、2.107,P균＜0.05);대조조환자치료후MMSE、ADAS-cog、ADL、NPI평분분별위(12.3±2.6)、(33.1±7.2)、(35.1±6.6)、(6.7±2.9)분,교치료전(11.0±2.5)、(44.9±6.9)、(42.2±6.6)、(10.9±3.5)분균유명현개선,치료전、후비교차이균유통계학의의(t치분별위2.101、-2.033、2.105、2.400,P균＜0.05);량조환자치료후MMSE、NPI평분비교차이유통계학의의(t치분별위2.553、2.176,P균＜0.05).관찰조화대조조환자불량반응발생솔분별위32.14％(18/56)、26.79％ (15/56),량조비교차이무통계학의의(P＞0.05).결론 미금강련용다내고제치료중、중도아이자해묵병환자적효과명현우우단용미금강적효과,차장기응용병불증가불량반응출현적풍험,연합응용안전、유효.
Objective To investigate clinical efficacy and safety of the memantine and donepezil in the treatment of moderate to severe Alzheimer's disease,in order to provide the basis for clinical treatment.Methods One hundred and twelve cases of moderate to severe Alzheimer's disease patients were given memantine plus donepezil(observation group) ,and single use of memantine treatment(control group), and the treatment for 24 weeks.Respectively before and after treatment, Mini Mental State Scale (MMSE), Alzheimer' s disease assessment scale (ADAS-cog), Alzheimer' s disease collaborative learning, daily life ability questionnaire (ADCS-ADL) ,and neuropsychological questionnaire (NPI) score, and adverse reactions were observed in the process of two kinds of therapy, the efficacy and safety of two kinds of treatment methods were evaluated.Results After treatment, the patients in observation group with MMSE, ADAS-cog, ADL and NPI evaluation results were (12.1 ± 2.1), (32.9 ± 8.3), (33.4 ± 5.0), (6.1 ± 3.1) scores, significantly improved compared with scoring (9.9±2.8), (46.2±7.6), (42.1±6.0), (10.5±2.9) scores before treatment,and the differences were statistically significant (t =2.138,-2.411,2.398, 2.107 respectively, P ＜ 0.05).The control group after treatment in patients with MMSE, ADAS-cog, ADL and NPI evaluation results were (12.3±2.6), (33.1 ±7.2), (35.1 ±6.6), (6.7 ± 2.9) scores, significantly improved compared with scoring 11.0 ± 2.5,44.9 ± 6.9,42.2 ±6.6,10.9 ± 3.5 before treatment, and the difference had statistical significanc (t =2.101,-2.033,2.105, 2.400 respectively, P＜0.05).After treatment, the difference of patients in the two groups of MMSE, NPI score had statistical significance(t =2.553,2.176, P＜0.05).The adverse reactions in two group respectively were 32.14％ (18/56) and 26.79％ (15/56), less difference was no statistical significance (P＞0.05).Vital signs checks,regular laboratory examination and ECG examination showed no obvious abnormalities.Conclusion Memantine combined with donepezil in the treatment of moderate and severe AD patients is superior to the singleeffect of memantine, and long-term use will not increase the risk of adverse reactions, which is safe and effective in the combined application.
